If Bis is superior to Dox given more doses of Bis can be administered instead of Dox (as you have mentioned above) then any potential BP acquiring us would have the potential opportunity to replace Dox as SOC with Bis if they can convince the clinicians? That itself is a huge upside, isn’t it?
Ann: Race Appoints George Clinical for Phase 1 Trial of RC220, page-82
-
- There are more pages in this discussion • 65 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
